| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Wetzell, V, et al.
(author)
-
Velocity dispersions of clusters in the Dark Energy Survey Y3 redMaPPer catalogue
- 2022
-
In: Monthly notices of the Royal Astronomical Society. - : Royal Astronomical Society. - 0035-8711 .- 1365-2966. ; 514:4, s. 4696-4717
-
Journal article (peer-reviewed)abstract
- We measure the velocity dispersions of clusters of galaxies selected by the red-sequence Matched-filter Probabilistic Percolation (redMaPPer) algorithm in the first three years of data from the Dark Energy Survey (DES), allowing us to probe cluster selection and richness estimation, λ, in light of cluster dynamics. Our sample consists of 126 clusters with sufficient spectroscopy for individual velocity dispersion estimates. We examine the correlations between cluster velocity dispersion, richness, X-ray temperature, and luminosity, as well as central galaxy velocity offsets. The velocity dispersion–richness relation exhibits a bimodal distribution. The majority of clusters follow scaling relations between velocity dispersion, richness, and X-ray properties similar to those found for previous samples; however, there is a significant population of clusters with velocity dispersions that are high for their richness. These clusters account for roughly 22 per cent of the λ < 70 systems in our sample, but more than half (55 per cent) of λ < 70 clusters at z > 0.5. A couple of these systems are hot and X-ray bright as expected for massive clusters with richnesses that appear to have been underestimated, but most appear to have high velocity dispersions for their X-ray properties likely due to line-of-sight structure. These results suggest that projection effects contribute significantly to redMaPPer selection, particularly at higher redshifts and lower richnesses. The redMaPPer determined richnesses for the velocity dispersion outliers are consistent with their X-ray properties, but several are X-ray undetected and deeper data are needed to understand their nature.
|
|
| 5. |
- Turner, D. J., et al.
(author)
-
The XMM Cluster Survey : an independent demonstration of the fidelity of the eFEDS galaxy cluster data products and implications for future studies
- 2022
-
In: Monthly notices of the Royal Astronomical Society. - : Oxford University Press. - 0035-8711 .- 1365-2966. ; 517:1, s. 657-674
-
Journal article (peer-reviewed)abstract
- We present the first comparison between properties of clusters of galaxies detected by the eROSITA Final Equatorial-Depth Survey (eFEDS) and the XMM Cluster Survey (XCS). We have compared, in an ensemble fashion, properties from the eFEDS X-ray cluster catalogue with those from the Ultimate XMM eXtragaLactic (XXL) survey project (XXL-100-GC). We find the redshift and temperature (T-X) distributions to be similar, with a larger proportion of clusters above 4 keV in the XXL-100-GC sample; fractional temperature uncertainties are significantly larger in eFEDS compared to XXL. We find 62 eFEDS cluster candidates with XMM data (eFEDS-XMM sample); 10 do not have good enough XMM data to confirm or deny, 11 are classed as sample contaminants, and 4 have their X-ray flux contaminated by another source. The majority of eFEDS-XMM sources have longer XMM exposures than eFEDS, and most eFEDS positions are within 100 kpc of XCS positions. Our eFEDS-XCS sample of 37 clusters is used to calculate minimum sample contamination fractions of similar to 18 and similar to 9 per cent in the eFEDS X-ray and optically confirmed samples, respectively, in general agreement with eFEDS findings. We directly compare 29 X-ray luminosities (L-X) measured by eFEDS and XCS, finding excellent agreement. Eight clusters have a T-X measured by XCS and eFEDS, and we find that XMM temperatures are 25 +/- 9 per cent larger than their eROSITA counterparts. Finally, we construct L-X-T-X scaling relations based on eFEDS and XCS measurements, which are in tension; the tension is decreased when we measure a third scaling relation with calibrated XCS temperatures.
|
|
| 6. |
- Price, RB, et al.
(author)
-
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
- 2022
-
In: Molecular psychiatry. - : Springer Science and Business Media LLC. - 1476-5578 .- 1359-4184. ; 27:1112, s. 5096-5112
-
Journal article (peer-reviewed)abstract
- Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized controlled trials of IV ketamine that recruited individuals with a relevant psychiatric diagnosis (e.g., unipolar or bipolar depression; post-traumatic stress disorder), included one or more control arms, did not provide any other study-administered treatment in conjunction with ketamine (although clinically prescribed concurrent treatments were allowable), and assessed outcome using either the Montgomery-Åsberg Depression Rating Scale or the Hamilton Rating Scale for Depression (HRSD-17). Individual patient-level data for at least one outcome was obtained from 17 of 25 eligible trials [pooled n = 809]. Rates of participant-level data availability across 33 moderators that were solicited from these 17 studies ranged from 10.8% to 100% (median = 55.6%). After data harmonization, moderators available in at least 40% of the dataset were tested sequentially, as well as with a data-driven, combined moderator approach. Robust main effects of ketamine on acute [~24-hours; β*(95% CI) = 0.58 (0.44, 0.72); p < 0.0001] and post-acute [~7 days; β*(95% CI) = 0.38 (0.23, 0.54); p < 0.0001] depression severity were observed. Two study-level moderators emerged as significant: ketamine effects (relative to placebo) were larger in studies that required a higher degree of previous treatment resistance to federal regulatory agency-approved antidepressant medications (≥2 failed trials) for study entry; and in studies that used a crossover design. A comprehensive data-driven search for combined moderators identified statistically significant, but modest and clinically uninformative, effects (effect size r ≤ 0.29, a small-medium effect). Ketamine robustly reduces depressive symptoms in a heterogeneous range of patients, with benefit relative to placebo even greater in patients more resistant to prior medications. In this largest effort to date to apply precision medicine approaches to ketamine treatment, no clinical or demographic patient-level features were detected that could be used to guide ketamine treatment decisions.Review Registration: PROSPERO Identifier: CRD42021235630
|
|
| 7. |
|
|
| 8. |
- Martin, DP, et al.
(author)
-
Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function
- 2022
-
In: bioRxiv : the preprint server for biology. - : Cold Spring Harbor Laboratory.
-
Journal article (other academic/artistic)abstract
- Among the 30 non-synonymous nucleotide substitutions in the Omicron S-gene are 13 that have only rarely been seen in other SARS-CoV-2 sequences. These mutations cluster within three functionally important regions of the S-gene at sites that will likely impact (i) interactions between subunits of the Spike trimer and the predisposition of subunits to shift from down to up configurations, (ii) interactions of Spike with ACE2 receptors, and (iii) the priming of Spike for membrane fusion. We show here that, based on both the rarity of these 13 mutations in intrapatient sequencing reads and patterns of selection at the codon sites where the mutations occur in SARS-CoV-2 and related sarbecoviruses, prior to the emergence of Omicron the mutations would have been predicted to decrease the fitness of any genomes within which they occurred. We further propose that the mutations in each of the three clusters therefore cooperatively interact to both mitigate their individual fitness costs, and adaptively alter the function of Spike. Given the evident epidemic growth advantages of Omicron over all previously known SARS-CoV-2 lineages, it is crucial to determine both how such complex and highly adaptive mutation constellations were assembled within the Omicron S-gene, and why, despite unprecedented global genomic surveillance efforts, the early stages of this assembly process went completely undetected.
|
|
| 9. |
- Wilkinson, John L., et al.
(author)
-
Pharmaceutical pollution of the world's rivers
- 2022
-
In: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 119:8
-
Journal article (peer-reviewed)abstract
- Environmental exposure to active pharmaceutical ingredients (APIs) can have negative effects on the health of ecosystems and humans. While numerous studies have monitored APIs in rivers, these employ different analytical methods, measure different APIs, and have ignored many of the countries of the world. This makes it difficult to quantify the scale of the problem from a global perspective. Furthermore, comparison of the existing data, generated for different studies/regions/continents, is challenging due to the vast differences between the analytical methodologies employed. Here, we present a global-scale study of API pollution in 258 of the world's rivers, representing the environmental influence of 471.4 million people across 137 geographic regions. Samples were obtained from 1,052 locations in 104 countries (representing all continents and 36 countries not previously studied for API contamination) and analyzed for 61 APIs. Highest cumulative API concentrations were observed in sub-Saharan Africa, south Asia, and South America. The most contaminated sites were in low- to middle-income countries and were associated with areas with poor wastewater and waste management infrastructure and pharmaceutical manufacturing. The most frequently detected APIs were carbamazepine, metformin, and caffeine (a compound also arising from lifestyle use), which were detected at over half of the sites monitored. Concentrations of at least one API at 25.7% of the sampling sites were greater than concentrations considered safe for aquatic organisms, or which are of concern in terms of selection for antimicrobial resistance. Therefore, pharmaceutical pollution poses a global threat to environmental and human health, as well as to delivery of the United Nations Sustainable Development Goals.
|
|
| 10. |
|
|
